<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551733</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000573340</org_study_id>
    <secondary_id>CTI-PGT-07-00400</secondary_id>
    <secondary_id>EUDRACT-2007-004167-22</secondary_id>
    <nct_id>NCT00551733</nct_id>
  </id_info>
  <brief_title>Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol &gt;30 pg/mL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel
      poliglumex, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. It is not yet known whether giving carboplatin
      together with paclitaxel poliglumex is more effective than giving carboplatin together with
      paclitaxel in treating non-small cell lung cancer.

      PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglumex to
      see how well they work compared with carboplatin and paclitaxel in treating women with stage
      III, stage IV, or recurrent non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the overall survival of patients with chemotherapy-naïve stage IIIB or IV or
           recurrent non-small cell lung cancer treated with paclitaxel poliglumex and carboplatin
           vs paclitaxel and carboplatin.

      Secondary

        -  Compare the progression-free survival of women treated with these regimens.

        -  Compare the disease control in women treated with these regimens.

        -  Compare the clinical benefit in women treated with these regimens.

        -  Compare the response rate in women treated with these regimens.

        -  Compare the quality of life of women treated with these regimens.

        -  Compare the safety and tolerability in women treated with these regimens.

      OUTLINE: This is a multicenter study.

      Patients are stratified according to age (≥ 60 vs &lt; 60 years old), geographical location
      (United States of America, Canada, or Australia vs the rest of the world), extent of disease
      (independent of brain metastases, i.e., brain metastases are not considered in determining
      extent of disease) (intrathoracic disease only vs extrathoracic disease), and ECOG
      performance status (0 or 1 vs 2). Patients will be randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin
           IV over 30 minutes on day 1.

        -  Arm II: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30
           minutes on day 1.

      In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, before each course, and at the completion of study
      treatment by the Pain Assessment Patient Questionnaire, the Pulmonary Symptom Index, and the
      Functional Assessment of Cancer Therapy- Lung Cancer Subscale (FACT-LCS) (only in countries
      in which a validated translation is currently available).

      After completion of study therapy, patients are followed at least monthly.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit as defined by use of opiates, growth factors, and transfusions,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by complete response or partial response per RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Fact-LCS Scores and Pulmonary Symptom Index (PSI) Scores and Pain Scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by NCI CTCAE Version 3</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel poliglumex</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer
             (NSCLC)

               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a
                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone
                  is not acceptable for determining cell type

          -  Must meet one of the following criteria:

               -  Recurrent disease following completion of radiation or surgery

               -  Stage IIIB disease and not a candidate for combined modality therapy (primary
                  radiation therapy or surgery)

               -  Stage IV disease

          -  Patients may have either measurable or nonmeasurable disease according to RECIST
             criteria

          -  Baseline estradiol &gt; 30 pg/mL

               -  Patients on hormone replacement therapy are eligible provided baseline estradiol
                  &gt; 30 pg/mL

          -  Patients with known brain metastases must have received standard antitumor treatment
             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS
             metastases as defined by the site's institutional standards

               -  Neurologic function must have been stable for 2 weeks before randomization and
                  patients must either be off steroid therapy for their brain metastases or on a
                  tapering regimen

               -  Patients must have recovered from therapy for their brain metastases with no
                  evidence of significant unstable neurological symptoms within the 4 weeks before
                  study randomization

          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell
             histology

        PATIENT CHARACTERISTICS:

          -  Female

          -  ECOG performance score 0-2

          -  Life expectancy ≥ 12 weeks

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL (may be achieved with transfusion)

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or other
             hereditary bilirubin defects may be included regardless of bilirubin levels)

          -  SGOT and SGPT ≤ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if
             due to liver metastases)

          -  Alkaline phosphatase ≤ 2.5 times ULN except for elevated alkaline phosphatase with
             laboratory documentation that demonstrates bone origin

          -  No pregnant women or nursing mothers

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

          -  No known hypersensitivity to study drugs or excipients

          -  Meets all of the following criteria:

               -  No weight loss &gt; 10% in previous 6 months

               -  Lactate dehydrogenase (LDH) ≤ 600 IU/L (central laboratory) regardless of weight
                  loss

               -  LDH ≤ 400 IU/L (central laboratory) and no weight loss ≥ 5% in previous 6 months

               -  BMI ≤ 35

          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin
             cancer

          -  No neuropathy grade 2 or greater

          -  No clinically significant active infection for which active therapy is underway

          -  No unstable medical conditions including unstable angina or myocardial infarction
             within the past 6 months

               -  Patients with evidence of cardiac conduction abnormalities are eligible if their
                  cardiac status is stable

          -  No circumstance that would preclude completion of the study or the required follow-up

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from major surgery

          -  At least 7 days since prior local palliative radiotherapy

          -  At least 30 days since prior radiation therapy with curative intent

          -  At least 4 weeks since prior investigational therapy, unless local requirements are
             more stringent

          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic
             radiosensitizers used to treat brain metastases or any biologic agents

          -  No concurrent non-protocol-specified systemic antitumor therapy

          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this
             disease

          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone
             metastases for palliative purposes or radiotherapy for a condition other than NSCLC
             that was ongoing at the time of randomization)

               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic
                  disease) may be treated while on study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred B. Oldham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CTI BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Medical Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giraldo Kato, MD</last_name>
      <phone>480-767-7337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Providence Saint Joseph Medical Cente</last_name>
      <phone>818-847-3220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Cancer Care - Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025-4404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Kosmo, MD</last_name>
      <phone>760-737-2666</phone>
      <email>makosmo@swcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Associates, Incorporated</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Chua, MD</last_name>
      <phone>323-724-8769</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Stanford Cancer Center</last_name>
      <phone>650-498-7061</phone>
      <email>cctoffice@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Broward Oncology Associates</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308-1414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis R. Barreras, MD, FACP</last_name>
      <phone>954-771-0692</phone>
      <email>barrerasl@mindspring.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Institute for Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick N. Wittlin, MD</last_name>
      <phone>954-964-6881</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush Cancer Institute at Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Rush Cancer Institute at Rush Univers</last_name>
      <phone>312-942-5498</phone>
      <email>clinical_trials@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Limited - West</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjiv S. Modi, MD</last_name>
      <phone>815-730-3098</phone>
      <email>smod@jolietoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants - Naperville</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60565</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fariborze B. Barhamand, MD</last_name>
      <phone>630-369-1501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields</name>
      <address>
        <city>Olympia Fields</city>
        <state>Illinois</state>
        <zip>60461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Saint James Hospital and Health Cent</last_name>
      <phone>708-679-2217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Haute Terre</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montaser Shaheen, MD</last_name>
      <phone>812-234-5707</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Indiana</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Center of Indiana</last_name>
      <phone>812-945-4000 ext. 113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Medicine of Vincennes Clinical Trial Center</name>
      <address>
        <city>Vincennes</city>
        <state>Indiana</state>
        <zip>47591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhash Sharma</last_name>
      <phone>812-895-8009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Michigan Regional Cancer and Blood Center</name>
      <address>
        <city>Free Soil</city>
        <state>Michigan</state>
        <zip>49411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed S. Behairy, MD</last_name>
      <phone>231-757-1260</phone>
      <email>jjohnson@wmrcbc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newland Medical Associates PC - Southfield</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anibal Drelichman, MD, MPH, FACP</last_name>
      <phone>248-552-0620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, PA at Forrest General</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Herrington, MD</last_name>
      <phone>601-288-8282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Columbia Comprehensive Cancer Care Cl</last_name>
      <phone>573-893-6404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Pendergrass, MD</last_name>
      <phone>816-333-1326</phone>
      <email>Kelly.Pendergrass@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Saint Louis University Cancer Center</last_name>
      <phone>314-977-4440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Las Vegas Cancer Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nutan Parikh, MD</last_name>
      <phone>702-471-7779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy MacKintosh, MD</last_name>
      <phone>775-328-1828</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical and Mental Health Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doru Paul, MD</last_name>
      <phone>718-579-4693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310-1699</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Richmond University Medical Center</last_name>
      <phone>718-818-2952</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoo G. Chun, MD</last_name>
      <phone>914-493-7514</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic, PC</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Mid Dakota Clinic, PC</last_name>
      <phone>701-530-6950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood and Cancer Center, Incorporated</name>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <zip>44406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudershan K. Garg, MD</last_name>
      <phone>330-533-3040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Aultman Cancer Center at Aultman Hosp</last_name>
      <phone>330-363-6891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apurva Mehta, MD</last_name>
      <phone>513-584-6178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Ozer, MD, PhD</last_name>
      <phone>405-271-4022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vita Hematology Oncology at St. Luke's Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna A. Niewiarowska, MD</last_name>
      <phone>610-866-0113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Centers of the Carolinas</last_name>
      <phone>864-241-6251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center, PLLC - Collierville</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Gravenor, MD</last_name>
      <phone>901-850-0272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-South Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Mid-South Cancer Center</last_name>
      <phone>901-763-0446</phone>
      <email>research@memphiscancercenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Regional Cancer Center - Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Southwest Regional Cancer Center - Ce</last_name>
      <phone>512-421-4163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lone Star Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Skimkus, MD</last_name>
      <phone>512-343-2103</phone>
      <email>bshimkusmd@lonestaroncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center at Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Mary Crowley Medical Research Center</last_name>
      <phone>214-370-1877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utah Hematology Oncology, PC</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent L. Hansen, MD</last_name>
      <phone>801-387-7150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Outreach Associates - Abingdon</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cancer Outreach Associates - Abingdon</last_name>
      <phone>276-676-1863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Pinder-Schenck, MD</last_name>
      <phone>206-223-6193 ext. 67792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cell Therapeutics, Incorporated</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cell Therapeutics, Incorporated</last_name>
      <phone>800-715-0944</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30. doi: 10.1097/JTO.0b013e3181753b4b.</citation>
    <PMID>18520802</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

